Publications

Authors:

Dalbeni, A; Cattazzo, F; Natola, L A; Zoncapè, M; Faccincani, D; Stefanini, B; Ravaioli, F; Villani, R; Auriemma, A; Sacerdoti, D

Title:

What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?

Year:

2025

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

A Stampa

Referee:

Sì

Name of journal:

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY

ISSN of journal:

1747-4124

N° Volume:

19

Number or Folder:

4

Page numbers:

389-398

Keyword:

Hepatocellular carcinoma; ICIs; TKI; randomized controlled trials; real-world evidence; systemic therapy

Short description of contents:

IntroductionHepatocellular carcinoma (HCC) remains a major global health concern, as it is the most common primary liver cancer and the fourth leading cause of cancer-related mortality.Areas coveredImmune checkpoint inhibitors (ICIs) have significantly shifted the treatment paradigm, offering promising survival outcomes. However, the controlled conditions of randomized clinical trials (RCTs) often fail to reflect real-world complexities, emphasizing the necessity for strong real-world evidence (RWE). RWE, in most cases derived from observational studies, provides critical insights into the effectiveness, safety, and tolerability of systemic therapies across diverse populations and settings. The authors searched MEDLINE, Ovid Embase, and Scopus for full-text published articles in any language from the inception to 30 June 2024.This review evaluates RWE on systemic therapies for advanced HCC, including tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, ICIs such as nivolumab and pembrolizumab, and combination therapies like atezolizumab/bevacizumab and durvalumab/tremelimumab.Areas coveredImmune checkpoint inhibitors (ICIs) have significantly shifted the treatment paradigm, offering promising survival outcomes. However, the controlled conditions of randomized clinical trials (RCTs) often fail to reflect real-world complexities, emphasizing the necessity for strong real-world evidence (RWE). RWE, in most cases derived from observational studies, provides critical insights into the effectiveness, safety, and tolerability of systemic therapies across diverse populations and settings. The authors searched MEDLINE, Ovid Embase, and Scopus for full-text published articles in any language from the inception to 30 June 2024.This review evaluates RWE on systemic therapies for advanced HCC, including tyrosine kinase inhibitors (TKIs) like sorafenib and lenvatinib, ICIs such as nivolumab and pembrolizumab, and combination therapies like atezolizumab/bevacizumab and durvalumab/tremelimumab.Expert opinionStudies reveal discrepancies in treatment efficacy and adverse event profiles between RCTs and routine clinical practice, underscoring the need for individualized treatment strategies. RWE highlights the influence of liver disease etiology, liver function, and tumor burden on treatment outcomes, guiding therapy selection.

Product ID:

145566

Handle IRIS:

11562/1161473

Last Modified:

May 21, 2025

Bibliographic citation:

Dalbeni, A; Cattazzo, F; Natola, L A; Zoncapè, M; Faccincani, D; Stefanini, B; Ravaioli, F; Villani, R; Auriemma, A; Sacerdoti, D, What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY» , vol. 19 , n. 4 , 2025 , pp. 389-398

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo